The Molecular Virology Basic Research Program (MVBRP) is an interdisciplinary basic research Program consisting of 17 independent but interactive laboratories with common interests in the molecular biology and immunology of viruses relevant to cancer and related topics. The overall goal of this Program is to facilitate research into the basic mechanisms of viral tumorigenesis and viral immunology;to conduct investigations that may lead to novel approaches to prevent or treat tumors associated with viruses;or to use viruses themselves as vaccines or oncolytic agents. Under the leadership of Daniel DiMaio, M.D., Ph.D., a tumor virologist who focuses on papillomaviruses, the MVBRP accomplishes these goals primarily by sponsoring the Molecular Virology and Oncology Group Meetings and the Steven Degar Memorial Lectureship, by encouraging and stimulating collaborative research, and by providing access to YCC funds and shared resources. Dr. DiMaio, along with other Program faculty, directs the graduate level course, The Molecular Biology of Animal Viruses. He is also the Principal Investigator of the NCI-funded Program Project Grant, Molecular Basis of Viral and Cellular Transformation, as well as an NCI-funded postdoctoral training grant in tumor virology and an NIAID-funded predoctoral training grant in virology. The distinguished faculty of this Program includes members of the National Academy of Sciences (Steitz) and the Institute of Medicine (Miller and Steitz). In aggregate, the Program members have received seven NIH MERIT Awards. There are now substantial efforts in the areas of basic tumor virology, vaccine development and viral immunology, and oncolytic viruses. In the last grant period, members of this Program published 243 cancer related papers, of which 4.1% were intra-programmatic and 18% inter-programmatic. Because viruses play a causal role in a substantial fraction of human tumors, studies carried out in this Program may eventually have an important impact on cancer prevention and treatment by revealing the mechanisms responsible for viral replication and tumorigenesis, thus identifying novel targets for translational efforts. In addition, these studies will reveal the mechanistic basis of biological phenomena that are relevant to the development and treatment of many cancers, including those not associated with viruses. The Molecular Virology Program currently has 18 members from 12 departments, with total research funding of $7.2 million direct costs ($10.6 million total costs), of which $6.3 million direct costs is peer-reviewed and $2.7 million direct costs is NCI-funded.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-32
Application #
8132521
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
32
Fiscal Year
2010
Total Cost
$33,424
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Jagannath, Sundar; Laubach, Jacob; Wong, Ellice et al. (2018) Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol 182:495-503
Liu, Xiaoni; Zhang, Shang-Min; McGeary, Meaghan K et al. (2018) KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations. Mol Cancer Ther :
Chae, Wook-Jin; Bothwell, Alfred L M (2018) Therapeutic Potential of Gene-Modified Regulatory T Cells: From Bench to Bedside. Front Immunol 9:303
Kim, Hanseul; Keum, NaNa; Giovannucci, Edward L et al. (2018) Garlic intake and gastric cancer risk: Results from two large prospective US cohort studies. Int J Cancer 143:1047-1053
Sarma, Elizabeth A; Kawachi, Ichiro; Poole, Elizabeth M et al. (2018) Social integration and survival after diagnosis of colorectal cancer. Cancer 124:833-840
Hartman, Douglas J; Ahmad, Fahad; Ferris, Robert L et al. (2018) Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral Oncol 86:278-287
Chen, Ling; Azuma, Takeshi; Yu, Weiwei et al. (2018) B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. Proc Natl Acad Sci U S A 115:3126-3131
Zhang, Jinhua; Song, Kun; Wang, Jun et al. (2018) S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity. Oncoimmunology 7:e1296996
Kelada, Olivia J; Decker, Roy H; Nath, Sameer K et al. (2018) High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors. Int J Radiat Oncol Biol Phys 102:174-183
Powles, Ryan L; Redmond, David; Sotiriou, Christos et al. (2018) Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 4:e181564

Showing the most recent 10 out of 675 publications